CMS: Next Day Disclosure Return
Apr 24 06:50 ET
CMS: Voluntary and Business Update Announcement New Drug Application of Desidustat Tablets Accepted in China
Apr 23 08:04 ET
CMS: Next Day Disclosure Return
Apr 17 07:32 ET
CMS: NOTIFICATION LETTER
Apr 17 05:18 ET
CMS: FORM OF PROXY
Apr 17 05:10 ET
CMS: NOTICE OF ANNUAL GENERAL MEETING
Apr 17 05:05 ET
CMS: PROPOSED RE-ELECTION OF THE RETIRING DIRECTORS, DECLARATION OF FINAL DIVIDEND, GENERAL MANDATES TO ISSUE SHARES AND TO REPURCHASE SHARES, PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND ADOPTION OF THE NEW MEMORANDUM AND ARTI
Apr 17 04:59 ET
CMS: Environmental, Social and Governance Report 2023
Apr 17 04:50 ET
CMS: Annual Report 2023
Apr 17 04:46 ET
CMS: Voluntary and Business Update Announcement New Drug Application of Ruxolitinib Cream Approved in Macau
Apr 16 10:34 ET
CMS: Next Day Disclosure Return
Apr 15 07:56 ET
CMS: Next Day Disclosure Return
Apr 12 07:28 ET
CMS: Next Day Disclosure Return
Apr 11 07:52 ET
CMS: Next Day Disclosure Return
Apr 10 07:04 ET
CMS: Next Day Disclosure Return
Apr 9 06:34 ET
CMS: Next Day Disclosure Return
Apr 8 07:35 ET
CMS: Next Day Disclosure Return
Apr 3 07:26 ET
CMS: Next Day Disclosure Return
Apr 2 07:52 ET
CMS: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
Apr 2 05:33 ET
CMS: Voluntary and Business Update Announcement Gaining Exclusive License for Oral Small-molecule JAK1 Inhibitor Povorcitinib for the Treatment of Vitiligo and Hidradenitis Suppurativa and Other Indications
Apr 1 06:22 ET
No Data
No Data